Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV : A Scientific Statement From the American Heart Association
As early and effective antiretroviral therapy has become more widespread, HIV has transitioned from a progressive, fatal disease to a chronic, manageable disease marked by elevated risk of chronic comorbid diseases, including cardiovascular diseases (CVDs). Rates of myocardial infarction, heart failure, stroke, and other CVD manifestations, including pulmonary hypertension and sudden cardiac death, are significantly higher for people living with HIV than for uninfected control subjects, even in the setting of HIV viral suppression with effective antiretroviral therapy. These elevated risks generally persist after demographic and clinical risk factors are accounted for and may be partly attributed to chronic inflammation and immune dysregulation. Data on long-term CVD outcomes in HIV are limited by the relatively recent epidemiological transition of HIV to a chronic disease. Therefore, our understanding of CVD pathogenesis, prevention, and treatment in HIV relies on large observational studies, randomized controlled trials of HIV therapies that are underpowered to detect CVD end points, and small interventional studies examining surrogate CVD end points. The purpose of this document is to provide a thorough review of the existing evidence on HIV-associated CVD, in particular atherosclerotic CVD (including myocardial infarction and stroke) and heart failure, as well as pragmatic recommendations on how to approach CVD prevention and treatment in HIV in the absence of large-scale randomized controlled trial data. This statement is intended for clinicians caring for people with HIV, individuals living with HIV, and clinical and translational researchers interested in HIV-associated CVD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:140 |
|---|---|
| Enthalten in: |
Circulation - 140(2019), 2 vom: 09. Juli, Seite e98-e124 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Feinstein, Matthew J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AHA Scientific Statements |
|---|
| Anmerkungen: |
Date Completed 01.04.2020 Date Revised 26.03.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1161/CIR.0000000000000695 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM297724649 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM297724649 | ||
| 003 | DE-627 | ||
| 005 | 20231225092622.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIR.0000000000000695 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0992.xml |
| 035 | |a (DE-627)NLM297724649 | ||
| 035 | |a (NLM)31154814 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Feinstein, Matthew J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV |b A Scientific Statement From the American Heart Association |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2020 | ||
| 500 | |a Date Revised 26.03.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a As early and effective antiretroviral therapy has become more widespread, HIV has transitioned from a progressive, fatal disease to a chronic, manageable disease marked by elevated risk of chronic comorbid diseases, including cardiovascular diseases (CVDs). Rates of myocardial infarction, heart failure, stroke, and other CVD manifestations, including pulmonary hypertension and sudden cardiac death, are significantly higher for people living with HIV than for uninfected control subjects, even in the setting of HIV viral suppression with effective antiretroviral therapy. These elevated risks generally persist after demographic and clinical risk factors are accounted for and may be partly attributed to chronic inflammation and immune dysregulation. Data on long-term CVD outcomes in HIV are limited by the relatively recent epidemiological transition of HIV to a chronic disease. Therefore, our understanding of CVD pathogenesis, prevention, and treatment in HIV relies on large observational studies, randomized controlled trials of HIV therapies that are underpowered to detect CVD end points, and small interventional studies examining surrogate CVD end points. The purpose of this document is to provide a thorough review of the existing evidence on HIV-associated CVD, in particular atherosclerotic CVD (including myocardial infarction and stroke) and heart failure, as well as pragmatic recommendations on how to approach CVD prevention and treatment in HIV in the absence of large-scale randomized controlled trial data. This statement is intended for clinicians caring for people with HIV, individuals living with HIV, and clinical and translational researchers interested in HIV-associated CVD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a AHA Scientific Statements | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a cardiovascular diseases | |
| 650 | 4 | |a preventive medicine | |
| 650 | 7 | |a Anti-Retroviral Agents |2 NLM | |
| 700 | 1 | |a Hsue, Priscilla Y |e verfasserin |4 aut | |
| 700 | 1 | |a Benjamin, Laura A |e verfasserin |4 aut | |
| 700 | 1 | |a Bloomfield, Gerald S |e verfasserin |4 aut | |
| 700 | 1 | |a Currier, Judith S |e verfasserin |4 aut | |
| 700 | 1 | |a Freiberg, Matthew S |e verfasserin |4 aut | |
| 700 | 1 | |a Grinspoon, Steven K |e verfasserin |4 aut | |
| 700 | 1 | |a Levin, Jules |e verfasserin |4 aut | |
| 700 | 1 | |a Longenecker, Chris T |e verfasserin |4 aut | |
| 700 | 1 | |a Post, Wendy S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation |d 1950 |g 140(2019), 2 vom: 09. Juli, Seite e98-e124 |w (DE-627)NLM000039020 |x 1524-4539 |7 nnns |
| 773 | 1 | 8 | |g volume:140 |g year:2019 |g number:2 |g day:09 |g month:07 |g pages:e98-e124 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/CIR.0000000000000695 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 140 |j 2019 |e 2 |b 09 |c 07 |h e98-e124 | ||